Hybrid assistive exoskeleton to support upper limb movement

Assessment of Feasibility, Functionality and Usability of an Hybrid Assistive Exoskeleton for Upper Limb: a Pilot Study

NA · Istituto Nazionale Assicurazione contro gli Infortuni sul Lavoro · NCT07000279

This study will try a hybrid assistive exoskeleton to help adults with upper limb weakness from stroke or brachial plexus injury perform everyday tasks.

Quick facts

PhaseNA
Study typeInterventional
Enrollment10 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorIstituto Nazionale Assicurazione contro gli Infortuni sul Lavoro (other)
Locations1 site (Budrio, Bologna)
Trial IDNCT07000279 on ClinicalTrials.gov

What this trial studies

Adults at least six months after stroke or brachial plexus injury with some preserved arm strength will use a hybrid exoskeleton while researchers test its functionality and usability. Participants will perform activities of daily living, a box-and-block task, and maximum reaching height tests while wearing the device. Inclusion requires Medical Research Council (MRC) muscle strength ≥2, cognitive ability to follow instructions, and no recent FES treatment or interfering implants. The work is conducted at a single center (Centro Protesi Inail, Budrio) and focuses on feasibility rather than long-term efficacy.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18–65 who are at least six months post-stroke or post-brachial plexus injury, have MRC muscle strength of 2 or higher in the affected arm, can follow instructions, and have no implants or recent FES treatment that would interfere.

Not a fit: Patients with MRC strength below 2, significant pain (NRS >4), other neurological or orthopedic impairments, cognitive impairment (MMSE <24), implantable devices that interfere with FES, pregnancy, or unstable medical conditions are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the device could improve arm function and increase independence in everyday activities for people with upper limb deficits.

How similar studies have performed: Active devices like MyoPro exist for elbow and wrist and there is supporting evidence for gravity compensation and FES, but hybrid upper-limb exoskeletons for everyday use remain relatively novel with limited clinical proof.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age between 18 and 65 years
* post-stroke or brachial plexus injuries patients
* upper limb motor deficit patients with Medical Research Council (MRC) Scale for Muscle Strength equal to or more than 2
* number of months after lesion higher than 6
* cognitive ability to follow instruction
* no Functional Electrical Stimulation (FES) treatment within 6 months prior to the enrollment
* absence of communication deficit

Exclusion Criteria:

* other nuerological or orthopaedic impairments
* pain in injuried upper limb (Numeric Rating Scale (NRS) higher than 4)
* cognitive impairments (Mini-Mental State Examination (MMSE) lower than 24)
* implantable devices that can interfere with FES
* muscle/neurological diseases that can get worse with FES
* fever or infection
* pregnancy or breastfeeding
* absence of patient informed consent in written form
* unstable medical condition

Where this trial is running

Budrio, Bologna

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Upper Limb Deficits, assistive exoskeleton, upper arm, post stroke, brachial plexus injury, orthesis, functional electrical stimulation, activity of daily living

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.